MENU
+Compare
CAPR
Stock ticker: NASDAQ
AS OF
Jul 21, 04:59 PM (EDT)
Price
$6.25
Change
-$0.62 (-9.01%)
Capitalization
286.59M

CAPR Capricor Therapeutics Forecast, Technical & Fundamental Analysis

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs... Show more

Industry: #Biotechnology
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CAPR with price predictions
Jul 18, 2025

CAPR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on July 11, 2025

CAPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 32 cases where CAPR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CAPR's RSI Indicator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in of 272 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 169 cases where CAPR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CAPR turned negative on July 11, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

CAPR moved below its 50-day moving average on July 11, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CAPR crossed bearishly below the 50-day moving average on June 26, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CAPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.245) is normal, around the industry mean (18.143). P/E Ratio (0.000) is within average values for comparable stocks, (58.647). CAPR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.460). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (14.006) is also within normal values, averaging (270.975).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CAPR is expected to report earnings to fall 10.38% to -47 cents per share on August 07

Capricor Therapeutics CAPR Stock Earnings Reports
Q2'25
Est.
$-0.47
Q1'25
Missed
by $0.21
Q4'24
Beat
by $0.01
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.01
The last earnings report on May 13 showed earnings per share of -52 cents, missing the estimate of -31 cents. With 3.52M shares outstanding, the current market capitalization sits at 286.59M.
A.I. Advisor
published General Information

General Information

Develops innovative products for the treatment of cardiovascular diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10865 Road to the Cure
Phone
+1 858 727-1755
Employees
102
Web
https://www.capricor.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MGYOY4.570.13
+2.93%
MOL Magyar Olaj-Es Gazipari RT
WMMVF2.900.07
+2.47%
Wal-Mart De Mexico S.A.B. de C.V.
BOMXF2.250.04
+1.58%
Bolsa Mexicana de Valores, S.A.B. de C.V.
LMEFF0.30N/A
N/A
Laurion Mineral Exploration Inc.
ROWKF0.35N/A
N/A
Renoworks Software, Inc.

CAPR and Stocks

Correlation & Price change

A.I.dvisor tells us that CAPR and QURE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CAPR and QURE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAPR
1D Price
Change %
CAPR100%
-3.91%
QURE - CAPR
32%
Poorly correlated
-1.38%
ARCT - CAPR
31%
Poorly correlated
-0.30%
SNDX - CAPR
31%
Poorly correlated
-2.17%
ABEO - CAPR
31%
Poorly correlated
-0.60%
WVE - CAPR
30%
Poorly correlated
+4.12%
More